IFM Investors Pty Ltd Grows Position in Thermo Fisher Scientific Inc. $TMO

IFM Investors Pty Ltd grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,625 shares of the medical research company’s stock after buying an additional 2,071 shares during the quarter. IFM Investors Pty Ltd’s holdings in Thermo Fisher Scientific were worth $36,680,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in TMO. High Note Wealth LLC lifted its holdings in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. Beacon Financial Strategies CORP bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. Olistico Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. Finally, Birchwood Financial Partners Inc. bought a new position in Thermo Fisher Scientific in the 4th quarter worth $29,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 1.2%

TMO opened at $500.36 on Wednesday. The stock has a 50-day moving average of $473.35 and a 200 day moving average of $518.92. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99. The firm has a market cap of $185.94 billion, a P/E ratio of 27.51, a P/E/G ratio of 2.24 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. DZ Bank began coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They set a “buy” rating and a $610.00 price target on the stock. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Wolfe Research began coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Finally, Barclays lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $605.09.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.